National Immunotherapy Cancer Research Foundation Inc
National Immunotherapy Cancer Research Foundation: High Assets, Low Program Spending
EIN: 223067246 · Flemington, NJ · NTEE: H30Z · Updated: 2026-04-04
Is National Immunotherapy Cancer Research Foundation Inc Legit?
Significant Concerns
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
National Immunotherapy Cancer Research Foundation Inc directs 15% of its spending to programs. This falls below the 65% benchmark. Donors may want to investigate further.
About National Immunotherapy Cancer Research Foundation Inc
National Immunotherapy Cancer Research Foundation Inc (EIN: 223067246) is a nonprofit organization based in Flemington, NJ, classified under NTEE code H30Z. The organization reported total revenue of $526K and total assets of $1.2M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of National Immunotherapy Cancer Research Foundation Inc's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates National Immunotherapy Cancer Research Foundation Inc with a Mission Score of 45 out of 100 (Fair). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 50%
- programs: 15%
- fundraising: 35%
According to IRS 990 filings, National Immunotherapy Cancer Research Foundation Inc allocates its expenses as follows: admin: 50%, programs: 15%, fundraising: 35%. Only 15% is directed toward programs, which may warrant further investigation by donors.
Executive Compensation Analysis
Executive compensation cannot be assessed as it is not disclosed in the provided data, which is a significant transparency concern for an organization with substantial assets.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Red Flags
The following concerns were identified during AI analysis of National Immunotherapy Cancer Research Foundation Inc's IRS 990 filings:
- In 2023, only $15,146 (approx. 10% of total expenses) was spent on programs, despite $1,051,896 in assets.
- Significant fluctuations in revenue, from $330,414 in 2019 to $4,423 in 2022, raise questions about funding stability and strategy.
- A high percentage of expenses consistently allocated to administrative and fundraising activities rather than direct program services.
- Lack of detailed information regarding executive compensation and specific program outcomes.
Strengths
The following positive indicators were identified for National Immunotherapy Cancer Research Foundation Inc:
- The organization maintains a healthy asset base, with $1,051,896 in 2023, indicating financial stability.
- Consistent filing of financial documents, demonstrating adherence to reporting requirements.
Frequently Asked Questions about National Immunotherapy Cancer Research Foundation Inc
Is National Immunotherapy Cancer Research Foundation Inc a legitimate charity?
Based on AI analysis of IRS 990 filings, National Immunotherapy Cancer Research Foundation Inc (EIN: 223067246) significant concerns. Mission Score: 45/100. 4 red flags identified, 2 strengths noted.
How does National Immunotherapy Cancer Research Foundation Inc spend its money?
National Immunotherapy Cancer Research Foundation Inc directs 15% of its spending to programs and services. The remaining budget covers administration and fundraising costs.
Are donations to National Immunotherapy Cancer Research Foundation Inc tax-deductible?
National Immunotherapy Cancer Research Foundation Inc is registered as a tax-exempt nonprofit (EIN: 223067246). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
What does National Immunotherapy Cancer Research Foundation Inc do?
National Immunotherapy Cancer Research Foundation Inc is a nonprofit organization in the Medical Research sector, located in Flemington, New Jersey. It is classified under NTEE code H30Z.
How much revenue does National Immunotherapy Cancer Research Foundation Inc have?
National Immunotherapy Cancer Research Foundation Inc reported total revenue of $526,399. Based on 14 IRS 990 filings on record.
What are National Immunotherapy Cancer Research Foundation Inc's total assets?
National Immunotherapy Cancer Research Foundation Inc holds total assets of $1,231,547 as reported in IRS 990 filings.
Where is National Immunotherapy Cancer Research Foundation Inc located?
National Immunotherapy Cancer Research Foundation Inc is based in Flemington, New Jersey.
What is National Immunotherapy Cancer Research Foundation Inc's EIN?
National Immunotherapy Cancer Research Foundation Inc's Employer Identification Number (EIN) is 223067246. This is the unique tax ID assigned by the IRS for tax-exempt organizations.
What type of nonprofit is National Immunotherapy Cancer Research Foundation Inc?
National Immunotherapy Cancer Research Foundation Inc is classified under NTEE code H30Z (Medical Research).
Is National Immunotherapy Cancer Research Foundation Inc a registered 501(c)(3)?
Yes, National Immunotherapy Cancer Research Foundation Inc is recognized as a tax-exempt organization by the IRS. EIN: 223067246.
Does National Immunotherapy Cancer Research Foundation Inc file IRS Form 990?
Yes, National Immunotherapy Cancer Research Foundation Inc has 14 IRS Form 990 filings on record. The most recent covers tax period 202312.
What was National Immunotherapy Cancer Research Foundation Inc's revenue in 2023?
In the 202312 filing period, National Immunotherapy Cancer Research Foundation Inc reported total revenue of $151,460, total expenses of $98,040, and net assets of $1,051,896.
Is National Immunotherapy Cancer Research Foundation Inc's revenue growing or declining?
National Immunotherapy Cancer Research Foundation Inc's revenue is growing. Revenue went from $4,423 (202212) to $151,460 (202312), a +3324.4% change. Based on 14 filings on record.
What is National Immunotherapy Cancer Research Foundation Inc's most recent 990 filing?
The most recent IRS Form 990 filing for National Immunotherapy Cancer Research Foundation Inc covers tax period 202312. It shows revenue of $151,460, expenses of $98,040, total assets of $1,051,896, and liabilities of $461,889.
How much does National Immunotherapy Cancer Research Foundation Inc spend on programs vs administration?
Based on IRS 990 analysis, National Immunotherapy Cancer Research Foundation Inc allocates approximately 15% of expenses to program services, 50% to administrative costs, and 35% to fundraising. Overhead costs appear high relative to program spending.
Is National Immunotherapy Cancer Research Foundation Inc a trustworthy charity?
Based on AI analysis of IRS 990 data, National Immunotherapy Cancer Research Foundation Inc shows mixed signals. Mission Score: 45/100 (Fair). 4 red flags identified. 2 strengths noted.
What are the red flags for National Immunotherapy Cancer Research Foundation Inc?
The following concerns were identified: In 2023, only $15,146 (approx. 10% of total expenses) was spent on programs, despite $1,051,896 in assets.. Significant fluctuations in revenue, from $330,414 in 2019 to $4,423 in 2022, raise questions about funding stability and strategy.. A high percentage of expenses consistently allocated to administrative and fundraising activities rather than direct program services.. Lack of detailed information regarding executive compensation and specific program outcomes.. These flags are based on automated analysis of IRS 990 public filings and should be verified independently.
What are National Immunotherapy Cancer Research Foundation Inc's strengths?
Positive indicators for National Immunotherapy Cancer Research Foundation Inc include: The organization maintains a healthy asset base, with $1,051,896 in 2023, indicating financial stability.. Consistent filing of financial documents, demonstrating adherence to reporting requirements.. These findings are derived from AI analysis of the organization's financial filings.
How does National Immunotherapy Cancer Research Foundation Inc compensate executives?
Executive compensation cannot be assessed as it is not disclosed in the provided data, which is a significant transparency concern for an organization with substantial assets. Executive compensation data is sourced from IRS 990 filings, which require disclosure of officer, director, and key employee pay.
Given the substantial assets and fluctuating revenue, what is the strategic plan for increasing program spending and impact?
The data suggests a need for a clear strategy to convert assets and fundraising efforts into direct program services, as current program spending is disproportionately low compared to administrative and fundraising costs.
How does the organization justify the high administrative and fundraising expenses relative to the minimal program expenditures?
With administrative and fundraising expenses consistently outweighing program spending (e.g., 2023: $98,040 total expenses with only $15,146 on programs), the organization needs to provide a detailed justification for these allocations and demonstrate their necessity for future program growth.
Filing History
IRS 990 filing history for National Immunotherapy Cancer Research Foundation Inc showing financial trends over 14 years of public records:
Over 14 years of IRS 990 filings (2010–2023), National Immunotherapy Cancer Research Foundation Inc's revenue has declined by 34.5%, moving from $231K to $151K. Total assets increased by 79.1% over the same period, from $587K to $1.1M. Total functional expenses fell by 43.6%, from $174K to $98K. In its most recent filing year (2023), National Immunotherapy Cancer Research Foundation Inc reported a surplus of $53K, with revenue exceeding expenses. The organization holds $462K in liabilities against $1.1M in assets (debt-to-asset ratio: 43.9%), resulting in net assets of $590K.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. | |
|---|---|---|---|---|---|---|
| 2023 | $151K | $98K | $1.1M | $462K | — | — |
| 2022 | $4K | $136K | $1.1M | $626K | — | View 990 |
| 2021 | $6K | $78K | $1.4M | $750K | — | View 990 |
| 2020 | $14K | $1.0M | $1.6M | $875K | — | — |
| 2019 | $330K | $33K | $1.7M | $36K | — | View 990 |
| 2018 | $328K | $29K | $1.6M | $172K | — | View 990 |
| 2017 | $300K | $253K | $1.4M | $308K | — | View 990 |
| 2016 | $234K | $228K | $1.5M | $464K | — | View 990 |
| 2015 | $287K | $576K | $1.5M | $465K | — | View 990 |
| 2014 | $294K | $52K | $1.4M | $60K | — | View 990 |
| 2013 | $294K | $127K | $1.2M | $142K | — | View 990 |
| 2012 | $270K | $14K | $984K | $62K | — | View 990 |
| 2011 | $218K | $10K | $778K | $112K | — | View 990 |
| 2010 | $231K | $174K | $587K | $120K | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $151K, expenses of $98K, and assets of $1.1M (revenue +3324.4% year-over-year).
- 2022: Revenue of $4K, expenses of $136K, and assets of $1.1M (revenue -26.3% year-over-year).
- 2021: Revenue of $6K, expenses of $78K, and assets of $1.4M (revenue -57.0% year-over-year).
- 2020: Revenue of $14K, expenses of $1.0M, and assets of $1.6M (revenue -95.8% year-over-year).
- 2019: Revenue of $330K, expenses of $33K, and assets of $1.7M (revenue +0.7% year-over-year).
- 2018: Revenue of $328K, expenses of $29K, and assets of $1.6M (revenue +9.4% year-over-year).
- 2017: Revenue of $300K, expenses of $253K, and assets of $1.4M (revenue +28.3% year-over-year).
- 2016: Revenue of $234K, expenses of $228K, and assets of $1.5M (revenue -18.5% year-over-year).
- 2015: Revenue of $287K, expenses of $576K, and assets of $1.5M (revenue -2.5% year-over-year).
- 2014: Revenue of $294K, expenses of $52K, and assets of $1.4M (revenue +0.1% year-over-year).
- 2013: Revenue of $294K, expenses of $127K, and assets of $1.2M (revenue +8.9% year-over-year).
- 2012: Revenue of $270K, expenses of $14K, and assets of $984K (revenue +23.7% year-over-year).
- 2011: Revenue of $218K, expenses of $10K, and assets of $778K (revenue -5.5% year-over-year).
- 2010: Revenue of $231K, expenses of $174K, and assets of $587K.
Data Sources and Methodology
This transparency report for National Immunotherapy Cancer Research Foundation Inc is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.